Risankizumab, an Interleukin-23 Inhibitor, for Moderate-Severe Crohn’s Disease: Advancing Care Beyond Anti-TNF Therapy

Bharati Kochar, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Risankizumab as Induction Therapy for Crohn’s Disease: Results from the Phase 3 ADVANCE and MOTIVATE Induction Trials,” by D’Haens G, Panaccione R, Baert F, et al. Lancet [2022; 399: 2015-30].